At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.

Buoyed by $110m in funding three months ago, Capstan Medical has reported the first-in-human cases with the mitral technology ...

"Today marks a pivotal moment in the evolution of structural heart therapy," Capstan Medical CEO Maggie Nixon said.

Capstan CEO Maggie Nixon discusses first-in-human feedback, the all-at-once approach, regulatory strategy and the tricuspid ...

Early surgical or transcatheter aortic valve replacement is not typically recommended for severe aortic stenosis in the ...

The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art ...

The following is a summary of "Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated ...

A Tennessee mother’s pregnancy experience is serving as a powerful reminder of the importance of monitoring heart health during pregnancy.

Aortic stenosis, a narrowing of the aortic valve, is one of the most common and severe structural issues, particularly in ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Capstan Medical announced its first in-human cardiac valve replacements using its catheter-based robotic surgical platform.